FDA-Drug2017-08-16Class III
Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx only, Mfd for: Watson Laboratories, Inc., Corona, CA 92880, Mfd by: Patheon Pharmaceuticals, Inc., Cincinnati, OH 43215, NDC 0591-0844-15
Teva Pharmaceuticals USA
Hazard
Failed Moisture Limits: out of specification test results for water content obtained during stability testing.
Sold states
Product distributed to OH, IL, PA, MI, VA and CT
Affected count
2,880 cartons (30 unit dose blister pack per carton)
Manufactured in
1090 Horsham Rd, N/A, North Wales, PA, United States
Products
Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx only, Mfd for: Watson Laboratories, Inc., Corona, CA 92880, Mfd by: Patheon Pharmaceuticals, Inc., Cincinnati, OH 43215, NDC 0591-0844-15
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1058-2017Don't want to check this manually?
We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.
Get the Sunday Brief